Flt3.t-haNK

N/A

Report date: 2021/12/24 10:29:12

Base Information

Drug NameFlt3.t-haNK

Drug Alias NameFlt3.t-haNK

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitors

TargetsTyrosine-protein kinase receptor FLT3

Therapy Area/IndicationsHead and Neck Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNantkwest Inc Immunitybio Inc

China Registration ClassN/A

Develop Information

Active CompaniesImmunitybio Inc Nantkwest Inc

Inactive CompaniesN/A

Active IndicationsHead and Neck Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A